News
Philly's Context Therapeutics will now test prostate cancer drug on breast cancer
Context Therapeutics, a University City firm set up to develop new cancerfighting drugs, has bought Apristor, the last drug owned by Arno Therapeutics, a Flemington, N.J., drug company that is dissolving.
Drexel Researcher Nominated As 2017 STAT Wunderkind
Oyer is now a postdoc at Drexel University studying Sigma 1, a so-called “chaperone protein” that influences other proteins and pathways involved in the amount of stress cells endure.
Researchers at Sidney Kimmel Cancer Center at Thomas Jefferson University Promise New Directions for Targeting Prostate Cancer
A team of Sidney Kimmel Cancer Center (SKCC) investigators from Thomas Jefferson University and Drexel University has recently published a new study in the journal Cancer Research that sheds light on a key mechanism of prostate cancer progression.